SCHEMBL25613097

SCHEMBL25613097

CC(C)(C)c1cc2cc[nH]c2nc1OCC1CCN1

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ CHRNB4 P30926 2/20 0.39
▸ CHRNA3 P32297 2/20 0.39
▸ CHRNB2 P17787 1/20 0.38
▸ CHRNA5 P30532 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613093 0.92 CHRNA3 (0.42) CHRNB4CHRNA3CHRNB2CHRNA5
SCHEMBL25613089 0.84 CNR2 (0.42) —
SCHEMBL25613094 0.84 CDK2 (0.38) —
SCHEMBL25613092 0.84 CDK2 (0.40) —
SCHEMBL25650732 0.83 CHRNB4 (0.36) CHRNB4CHRNA3CHRNB2CHRNA5
SCHEMBL24005768 0.81 CHRNB2 (0.39) CHRNB4CHRNA3CHRNB2CHRNA5
SCHEMBL25613103 0.80 CHRNA3 (0.42) CHRNB4CHRNA3CHRNB2
SCHEMBL25613037 0.79 FEN1 (0.39) —
SCHEMBL25613106 0.79 FEN1 (0.33) —
SCHEMBL25613114 0.78 CHRNB4 (0.46) CHRNB4CHRNA3CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 CHRNB4 4865/4885CHRNA3 4861/4885CHRNB2 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback